Stock listing
Turquoise:ALVOS Alvotech Share Price
UK listing (Turquoise) of Alvotech · home listing NASDAQ:ALVO
Follow Alvotech into a list and get an email when it puts out news.
Home listing price · NASDAQ:ALVO
$4.12 USD -0.43 (-9.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ALVO
- Day range
- $4.09 – $4.29 USDNov 20, 2026
- Volume
- 826,571 sharesNov 20, 2026
- Market cap
- $1.47B USDAt the close on Nov 20, 2026 · price × 356.8M shares outstanding
- 52-week range
- $2.94 – $6.53 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5.99M USDMedian day 946,927 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALVO · Home | $4.12 USD | -0.43 (-9.5%) | 826,571 | $4.26 | $4.29 | $4.09 | $4.55 | Close on Nov 20, 2026 |
| Frankfurt:Z45 | €3.67 EUR | -0.17 (-4.4%) | — | €3.68 | €3.69 | €3.67 | €3.84 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALVO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.12 | -0.43 | -9.5% | $4.26 | $4.29 | $4.09 | 826,571 | |
| $4.55 | +0.18 | +4.1% | $4.375 | $4.67 | $4.35 | 1,561,440 | |
| $4.37 | -0.035 | -0.8% | $4.40 | $4.48 | $4.21 | 1,515,211 | |
| $4.405 | +0.215 | +5.1% | $4.16 | $4.59 | $4.15 | 1,027,644 | |
| $4.19 | -0.48 | -10.3% | $4.58 | $4.63 | $4.135 | 2,091,332 | |
| $4.67 | -0.25 | -5.1% | $4.49 | $4.76 | $4.31 | 2,990,091 | |
| $4.92 | +0.04 | +0.8% | $4.94 | $5.03 | $4.87 | 798,114 | |
| $4.88 | +0.19 | +4.1% | $4.73 | $4.897 | $4.665 | 946,927 | |
| $4.69 | -0.17 | -3.5% | $4.89 | $4.94 | $4.66 | 1,265,280 | |
| $4.86 | +0.31 | +6.8% | $4.57 | $4.935 | $4.57 | 1,015,933 | |
| $4.55 | -0.12 | -2.6% | $4.66 | $4.66 | $4.51 | 752,743 | |
| $4.67 | +0.13 | +2.9% | $4.56 | $4.765 | $4.47 | 668,970 | |
| $4.54 | +0.06 | +1.3% | $4.595 | $4.655 | $4.481 | 541,365 | |
| $4.48 | -0.17 | -3.7% | $4.75 | $4.75 | $4.47 | 1,552,224 | |
| $4.65 | -0.24 | -4.9% | $4.85 | $4.87 | $4.555 | 714,816 | |
| $4.89 | -0.05 | -1.0% | $4.95 | $5.00 | $4.845 | 373,199 | |
| $4.94 | +0.19 | +4.0% | $4.77 | $4.97 | $4.735 | 627,901 | |
| $4.75 | +0.13 | +2.8% | $4.62 | $4.765 | $4.60 | 733,316 | |
| $4.62 | +0.04 | +0.9% | $4.57 | $4.635 | $4.52 | 584,879 | |
| $4.58 | -0.21 | -4.4% | $4.78 | $4.78 | $4.565 | 666,200 | |
| $4.79 | -0.34 | -6.6% | $5.07 | $5.07 | $4.79 | 926,486 | |
| $5.13 | +0.01 | +0.2% | $5.14 | $5.24 | $5.115 | 480,520 | |
| $5.12 | +0.09 | +1.8% | $5.40 | $5.45 | $5.085 | 1,302,195 | |
| $5.03 | +0.03 | +0.6% | $5.13 | $5.15 | $5.02 | 907,210 | |
| $5.00 | -0.31 | -5.8% | $5.27 | $5.30 | $4.95 | 1,059,087 | |
| $5.31 | +0.14 | +2.7% | $5.15 | $5.39 | $5.131 | 1,156,272 | |
| $5.17 | -0.21 | -3.9% | $5.32 | $5.51 | $5.15 | 1,058,173 | |
| $5.38 | -0.12 | -2.2% | $5.51 | $5.64 | $5.311 | 1,214,000 | |
| $5.50 | -0.28 | -4.8% | $5.79 | $5.89 | $5.44 | 841,000 | |
| $5.78 | +0.11 | +1.9% | $5.67 | $5.805 | $5.565 | 707,100 | |
| $5.67 | -0.18 | -3.1% | $5.83 | $5.83 | $5.605 | 668,900 | |
| $5.85 | -0.29 | -4.7% | $6.10 | $6.14 | $5.845 | 864,600 | |
| $6.14 | +0.03 | +0.5% | $6.07 | $6.17 | $6.00 | 1,218,300 | |
| $6.11 | +0.66 | +12.1% | $5.99 | $6.53 | $5.90 | 2,898,700 | |
| $5.45 | -0.17 | -3.0% | $5.61 | $5.70 | $5.43 | 750,900 | |
| $5.62 | -0.18 | -3.1% | $5.81 | $5.82 | $5.46 | 1,201,500 | |
| $5.80 | -0.12 | -2.0% | $5.95 | $5.97 | $5.76 | 1,135,500 | |
| $5.92 | -0.23 | -3.7% | $6.135 | $6.17 | $5.825 | 1,169,200 | |
| $6.15 | +0.40 | +7.0% | $5.73 | $6.17 | $5.675 | 1,435,700 | |
| $5.75 | -0.13 | -2.2% | $5.90 | $5.90 | $5.67 | 705,200 | |
| $5.88 | +0.07 | +1.2% | $5.75 | $6.06 | $5.75 | 1,198,000 | |
| $5.81 | -0.03 | -0.5% | $5.86 | $5.89 | $5.70 | 774,000 | |
| $5.84 | -0.04 | -0.7% | $5.90 | $5.97 | $5.715 | 975,900 | |
| $5.88 | +0.01 | +0.2% | $5.92 | $5.98 | $5.74 | 1,312,300 | |
| $5.87 | +0.53 | +9.9% | $5.40 | $5.985 | $5.395 | 3,527,100 | |
| $5.34 | +0.24 | +4.7% | $5.22 | $5.455 | $5.20 | 1,704,500 | |
| $5.10 | +0.08 | +1.6% | $5.40 | $5.53 | $5.10 | 3,864,100 | |
| $5.02 | -0.03 | -0.6% | $5.05 | $5.07 | $4.90 | 610,000 | |
| $5.05 | -0.24 | -4.5% | $5.225 | $5.26 | $5.035 | 674,200 | |
| $5.29 | +0.05 | +1.0% | $5.28 | $5.39 | $5.26 | 667,900 | |
| $5.24 | +0.03 | +0.6% | $5.21 | $5.34 | $5.14 | 540,900 | |
| $5.21 | +0.02 | +0.4% | $5.15 | $5.24 | $5.06 | 572,400 | |
| $5.19 | -0.13 | -2.4% | $5.26 | $5.32 | $5.142 | 632,600 | |
| $5.32 | -0.06 | -1.1% | $5.31 | $5.40 | $5.205 | 535,400 | |
| $5.38 | +0.04 | +0.7% | $5.37 | $5.47 | $5.275 | 673,700 | |
| $5.34 | +0.10 | +1.9% | $5.24 | $5.415 | $5.171 | 700,300 | |
| $5.24 | +0.05 | +1.0% | $5.08 | $5.265 | $4.98 | 1,028,900 | |
| $5.19 | +0.24 | +4.8% | $5.00 | $5.265 | $4.98 | 1,250,700 | |
| $4.95 | +0.07 | +1.4% | $4.84 | $5.00 | $4.82 | 878,300 | |
| $4.88 | -0.03 | -0.6% | $4.88 | $4.979 | $4.785 | 967,700 | |
| $4.91 | -0.14 | -2.8% | $4.98 | $4.99 | $4.782 | 890,000 | |
| $5.05 | -0.20 | -3.8% | $5.24 | $5.39 | $5.015 | 1,771,959 | |
| $5.25 | +0.82 | +18.5% | $4.79 | $5.359 | $4.715 | 3,178,120 | |
| $4.43 | +0.16 | +3.7% | $4.32 | $4.595 | $4.32 | 2,268,900 | |
| $4.27 | +0.28 | +7.0% | $3.89 | $4.37 | $3.75 | 1,370,300 |
- Ticker
- Turquoise:ALVOS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Turquoise
- Currency
- SEK
What changed lately
Latest news release · Nov 11, 2026
Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update
Latest earnings call · Nov 12, 2026
Alvotech (NASDAQ:ALVO) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 12, 2026
9M 2026 Earnings Presentation
Earnings · 31 slides
Latest news
Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update
Nov 11, 2026
Closed $4.67 (-5.1%) on Nov 12, 2026
Alvotech to Present at Upcoming Investor Conferences in November
Nov 2, 2026
Closed $4.48 (-3.7%) on Nov 2, 2026
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
Oct 28, 2026
Closed $4.94 (+4.0%) on Oct 28, 2026
Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch
Oct 20, 2026
Closed $5.12 (+1.8%) on Oct 20, 2026
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
Oct 14, 2026
Closed $5.17 (-3.9%) on Oct 14, 2026
Alvotech: Half yearly financial audit reports reviews 2026 10 07 13h09m51 (1)
Oct 12, 2026
Closed $5.50 (-4.8%) on Oct 12, 2026
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
Oct 6, 2026
Closed $5.85 (-4.7%) on Oct 7, 2026
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
Oct 5, 2026
Closed $6.11 (+12.1%) on Oct 5, 2026
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
Aug 31, 2026
Closed $5.19 (+4.8%) on Aug 31, 2026
Alvotech to present at upcoming investor conferences in September
Aug 27, 2026
Closed $4.88 (-0.6%) on Aug 27, 2026
Alvotech on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 49 in the last 12 months · 224 in all · newest Nov 11, 2026 · oldest 2022
- Calls
- 18 calls with a replay · 18 with a transcript · latest Nov 12, 2026
- Decks
- 12 decks · latest Nov 12, 2026
Where Alvotech is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALVO · Home listing | NASDAQ | United States | USD |
| OMXICE:ALVO | OMXICE | Iceland | ISK |
| Stockholm:ALVOSDB | Stockholm | Sweden | SEK |
| LS Exchange:A3DK8U | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3DK8U | Lang & Schwarz | Germany | EUR |
| gettex:Z45 | gettex | Germany | EUR |
| Frankfurt:Z450 | Frankfurt | Germany | EUR |
| BX Swiss:ALVO | BX Swiss | Switzerland | CHF |
| BOATS:ALVO | BOATS | United States | USD |
| Dusseldorf:Z450 | Dusseldorf | Germany | EUR |
| Frankfurt:Z45 | Frankfurt | Germany | EUR |
| Munich:Z45 | Munich | Germany | EUR |
| Stuttgart:Z45 | Stuttgart | Germany | EUR |
| BX Swiss:ALVOUSD | BX Swiss | Switzerland | USD |
| Dusseldorf:Z45 | Dusseldorf | Germany | EUR |
| Hamburg:Z45 | Hamburg | Germany | EUR |
| Turquoise:ALVOS · This page | Turquoise | United Kingdom | SEK |
Valuation
EV/sales 5.7× against a median of 15.5×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.78B USD
- P/E
- Loss
- EV/sales
- 5.7×
- EV/EBITDA
- 31.4×
- Price/book
- Negative equity
- Gross margin
- 60.5%
- Operating margin
- 9.6%
- Net margin
- −36.5%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.90
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Alvotech · NASDAQ:ALVO | US$1.47B | US$2.78B | n/a | 5.7× | 31.4× | n/a | −36.5% | n/a | 0.90 |
| Recursion Pharmaceuticals, Inc. · NASDAQ:RXRX | US$1.53B | US$987.7M | n/a | 14.5× | n/a | 1.7× | −697.1% | 0.0× | 2.83 |
| ABL Bio, Inc. · KRX:298380 | US$1.47B | US$1.34B | n/a | 52.7× | n/a | 11.5× | −229.4% | 0.0× | n/a |
| PELL Bio-Med Technology Co Ltd · TWSE:6949 | US$1.46B | US$1.40B | n/a | 1,591× | n/a | 18.7× | n/a | 0.1× | n/a |
| Mesoblast Limited · ASX:MSB | US$1.46B | US$1.42B | n/a | 82.4× | n/a | 2.4× | −593.9% | 0.2× | n/a |
| Damora Therapeutics, Inc. · NASDAQ:DMRA | US$1.44B | US$910.0M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 0.88 |
| Vir Biotechnology, Inc. · NASDAQ:VIR | US$1.44B | US$1.07B | n/a | 3.5× | n/a | 1.6× | −61.0% | 0.1× | 1.82 |
| Voronoi, Inc. · KRX:310210 | US$1.44B | US$1.39B | n/a | n/a | n/a | 27.9× | n/a | 0.5× | n/a |
| Kailera Therapeutics, Inc. · NASDAQ:KLRA | US$1.43B | US$539.5M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.28 |
| Sarepta Therapeutics, Inc. · NASDAQ:SRPT | US$1.43B | US$1.41B | n/a | 0.7× | n/a | 0.9× | −5.9% | 0.6× | 1.70 |
| LigaChem Biosciences Inc. · KRX:141080 | US$1.42B | US$1.14B | n/a | 15.5× | n/a | 4.8× | −180.9% | 0.0× | n/a |
| Median of the others | US$1.44B | US$1.24B | 15.5× | 2.7× | −205.1% | 0.1× | 1.70 |
Forecasts
3 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.036 · 4 analysts
- Revenue, year to Dec 2026
- 652.3M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Lisa Graver | Chief Executive Officer |
| Linda Jónsdóttir | Chief Financial Officer |
| Joseph E. McClellan | Chief Operating Officer |
| Benedikt Stefansson | VP Investor Relations and Global Communications IS |
| MediaBenedikt Stefansson | VP Investor Relations and Global CommunicationsSarah Macleod, Head of Global |
| Patrik Ling | VP of Investor Relations Scandinavia |
| Kathryn Gunnarsson | SVP Global Talent & People Experience |
| Anthony M. Maffia | Chief Quality and Regulatory Affairs Officer |
| Balaji Prasad | Chief Strategy Officer |
| Neha Patel | Chief Information Officer |
| Robert Wessman | Executive Chairman |
Board
| Director | Role |
|---|---|
| Robert Wessman | Executive Chairman |
Events
Calls
| Call | When | Status |
|---|---|---|
| Alvotech (NASDAQ:ALVO) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q2 2026 Earnings Call | Thu, Aug 20, 2026 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q1 2026 Earnings Call | Thu, May 07, 2026 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q4 2025 Earnings Call | Thu, Mar 19, 2026 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q2 2025 Earnings Call | Thu, Aug 14, 2025 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q4 2024 Earnings Call | Thu, Mar 27, 2025 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q2 2024 Earnings Call | Fri, Aug 16, 2024 · 8:00 AM ET | Replay |
All 18 calls
| Call | When | Status |
|---|---|---|
| Alvotech (NASDAQ:ALVO) Q1 2024 Earnings Call | Wed, May 22, 2024 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q4 2023 Earnings Call | Thu, Mar 21, 2024 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q3 2023 Earnings Call | Wed, Nov 29, 2023 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q2 2023 Earnings Call | Thu, Aug 31, 2023 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q1 2023 Earnings Call | Fri, May 19, 2023 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q4 2022 Earnings Call | Thu, Mar 02, 2023 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q3 2022 Earnings Call | Wed, Nov 16, 2022 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q2 2022 Earnings Call | Thu, Sep 01, 2022 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 11, 2026 · After close | −5.1% |
| Q2 2026 | Aug 19, 2026 · After close | +7.0% |
| Q1 2026 | May 5, 2026 · After close | +2.0% |
| Q4 2025 | Mar 18, 2026 | −6.3% |
| Q3 2025 | Nov 12, 2025 · After close | −1.4% |
| Q2 2025 | Aug 13, 2025 · After close | −5.4% |
| Q1 2025 | May 7, 2025 | +17.7% |
| Q4 2024 | Mar 26, 2025 · After close | −10.3% |
| Q3 2024 | Nov 13, 2024 · After close | +1.2% |
| Q2 2024 | Aug 15, 2024 · After close | +8.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 21, 2024 · After close | +0.4% |
| Q4 2023 | Mar 20, 2024 · After close | −1.1% |
| Q3 2023 | Nov 28, 2023 · After close | −4.1% |
| Q2 2023 | Aug 30, 2023 · After close | +1.8% |
| Q1 2023 | May 19, 2023 · Before open | +0.6% |
| Q4 2022 | Mar 1, 2023 · After close | +0.8% |
| Q3 2022 | Nov 15, 2022 · After close | +4.3% |
| Q2 2022 | Aug 31, 2022 · After close | −14.3% |
| Q1 2022 | May 16, 2022 · After close | 0.0% |
| Q4 2021 | Mar 30, 2022 · After close | +0.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 9M 2026 Earnings Presentation | Earnings | 31 slides | Nov 12, 2026 |
| H1 2026 Earnings Presentation | Earnings | 31 slides | Aug 20, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 21 slides | May 7, 2026 |
| FY2025 Earnings Presentation | Earnings | 19 slides | Mar 19, 2026 |
| FY2025 Earnings Presentation | Earnings | 36 slides | Mar 19, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 23 slides | Nov 13, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 12 slides | Aug 14, 2025 |
| SPAC Merger (May 2022) | SPAC merger | 80 slides | May 17, 2022 |
| Oaktree Acquisition Corp. II — SPAC Merger (March 2022) | SPAC merger | 84 slides | Mar 23, 2022 |
| SPAC Merger (March 2022) | SPAC merger | 84 slides | Mar 23, 2022 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| SPAC Merger (February 2022) | SPAC merger | 64 slides | Feb 15, 2022 |
| SPAC Merger (December 2021) | SPAC merger | 62 slides | Dec 7, 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Public offering of ordinary shares Closed: US$98M raised · US$3.75 a share · BofA Securities +2 Dealers: BofA Securities (co-lead), Jefferies (co-lead), Evercore ISI (co-lead) Use of proceeds: Continued development of biosimilar assets, working capital and general corporate purposes | Jun 18, 2026 | |
| Private placement of ordinary shares Announced: about US$67M · US$3.75 a share Use of proceeds: Continued development of biosimilar assets, working capital and general corporate purposes | Jun 18, 2026 | |
| Senior unsecured convertible bonds due 2030 Made bigger: US$108M · DNB Carnegie Dealers: DNB Carnegie (lead) Use of proceeds: Continued investment in the R&D pipeline, scaling up production and global product launches. | Dec 17, 2025 | |
| Private placement of sDRs and ordinary shares Closed: DNB Carnegie Investment Bank AB (publ) +3 Dealers: DNB Carnegie Investment Bank AB (publ) (co-lead), Citigroup Global Markets Limited (co-lead), Skandinaviska Enskilda Banken AB (publ) (co-lead), ACRO Securities HF (co-lead) Use of proceeds: Accelerate R&D activities, especially in Sweden after the Xbrane R&D acquisition, expand pipeline, and general corporate purposes | Jun 11, 2025 | |
| Public offering of swedish Depository Receipts (SDRs) Update: about SEK 39M · SEK 87.51 a receipt · DNB Markets, a part of DNB Bank ASA, Sweden Branch +2 Dealers: DNB Markets, a part of DNB Bank ASA, Sweden Branch, Carnegie Investment Bank, DNB Carnegie Investment Bank AB (publ) | May 19, 2025 | US$3.99M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 586.3M | 489.7M | 91.4M | 83.0M | 36.8M | 66.6M | 31.9M |
| Cost of revenue | 235.6M | 185.3M | 160.9M | 64.1M | 0 | 0 | |
| Gross profit | 350.8M | 304.4M | -69.4M | 18.9M | 36.8M | 66.6M | 31.9M |
| Research and development | 184.2M | 171.3M | 210.8M | 180.6M | 191.0M | 148.1M | 95.6M |
| Selling, general and administrative | 90.9M | 61.5M | 73.0M | 186.7M | 84.1M | 58.9M | 48.6M |
| Operating income | 78.2M | 69.6M | -354.9M | -346.4M | -235.5M | -137.5M | -61.4M |
| Depreciation and amortization | 37.9M | 31.3M | 24.2M | 20.4M | 18.2M | 16.4M | 14.6M |
| EBITDA | 116.1M | 100.9M | -330.6M | -326.0M | -217.3M | -121.1M | -46.8M |
| Interest expense | 149.2M | 303.2M | 267.2M | 188.4M | 117.4M | 161.6M | 95.8M |
| Income before tax | 136.3M | -217.6M | -651.0M | -551.6M | -149.2M | -291.8M | -209.4M |
| Income tax | 108.4M | 14.3M | -99.3M | -38.1M | -47.7M | -121.7M | 491.0K |
| Net income | 27.9M | -231.9M | -551.7M | -513.6M | -101.5M | -170.0M | -209.9M |
| Earnings per share, basic | 0.10 | -0.87 | -2.43 | -2.60 | -0.92 | -1.82 | -0.86 |
| Earnings per share, diluted | 0.10 | -0.87 | -2.43 | -2.60 | -0.92 | -1.82 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 172.4M | 51.4M | 11.2M | 66.4M | 17.6M | 31.7M | |
| Receivables | 69.7M | 160.2M | 41.3M | 33.0M | 29.4M | 33.1M | |
| Inventory | 220.1M | 127.9M | 74.4M | 71.5M | 39.1M | 9.65M | |
| Current assets | 574.0M | 455.0M | 194.8M | 230.7M | 119.8M | 86.2M | |
| Property, plant and equipment | 356.4M | 284.5M | 236.8M | 220.6M | 78.5M | 177.0M | |
| Goodwill | 12.8M | 11.3M | 12.1M | 11.6M | 12.4M | 13.4M | |
| Total assets | 1.49B | 1.22B | 950.1M | 828.4M | 598.0M | 474.4M | |
| Accounts payable | 126.1M | 67.1M | 80.6M | 49.2M | 28.6M | 12.0M | |
| Current liabilities | 304.1M | 193.4M | 260.9M | 167.3M | 111.8M | 51.0M | |
| Long-term debt | 1.26B | 1.04B | 922.1M | 744.7M | 398.1M | 565.4M | |
| Total debt | 1.30B | 1.07B | 960.2M | 764.6M | 400.9M | 567.9M | |
| Total liabilities | 1.77B | 1.63B | 1.88B | 1.39B | 733.6M | 1.34B | |
| Shareholders' equity | -284.5M | -412.8M | -932.5M | -564.4M | -135.6M | -867.2M | |
| Shares outstanding | 312.0M | 301.8M | 266.8M | 252.2M | 893.1K | 31.3M | 243.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -50.2M | -236.8M | -312.2M | -312.4M | -228.2M | -74.3M | -88.5M |
| Capital spending | -64.5M | -53.7M | -33.2M | -37.9M | -20.5M | -7.49M | -8.05M |
| Free cash flow | -114.7M | -290.5M | -345.4M | -350.3M | -248.6M | -81.8M | -96.6M |
| Cash from investing | -104.2M | -18.9M | -46.3M | -63.5M | -40.6M | -16.9M | -12.9M |
| Cash from financing | 270.8M | 297.3M | 301.3M | 424.9M | 254.8M | 55.4M | 116.4M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | |
| Share buybacks | -9.80M | ||||||
| Change in cash | 116.4M | 41.6M | -57.2M | 49.0M | -14.0M | -35.8M | 15.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 20, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 14, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 7, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 31, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 21, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 29, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 304 filings. Open Filings
Cap table
Built by 6ix from Alvotech’s releases · as of Jun 18, 2026
- Common shares
- 356,817,038
- Fully diluted
- 356,817,038
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 356,817,038 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 356,817,038 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| ALVOTECHBenedikt Stefansson | VP Investor Relations and Global · Oct 6, 2025 – Nov 5, 2026 · Past |
| Anthony M. Maffia | Chief Quality and Regulatory Affairs Officer · Since at least Mar 18, 2026 |
| Balaji V. Prasad | Chief Strategy Officer · Since at least Mar 27, 2025 |
| Benedikt Stefansson | VP Investor Relations and Global Communications IS · Since at least Dec 31, 2025 |
| CommunicationsBenedikt Stefansson | VP Global Communications and Investor · Sep 19, 2025 – Nov 5, 2026 · Past |
| Joseph E. McClellan | Chief Operating Officer · Since at least Oct 20, 2026 |
| Kathryn Gunnarsson | SVP Global Talent & People Experience · Since at least Nov 5, 2026 |
| Linda Jónsdóttir | Chief Financial Officer · Since at least Jul 10, 2025 |
| Lisa Graver | Chief Executive Officer · Since at least Jan 6, 2026 |
| MediaBenedikt Stefansson | VP Investor Relations and Global CommunicationsSarah Macleod, Head of Global · Since at least Dec 31, 2025 |
All 13 people
| Person | Seat |
|---|---|
| Neha Patel | Chief Information Officer · Since at least Nov 5, 2026 |
| Patrik Ling | VP of Investor Relations Scandinavia · Since at least Aug 20, 2025 |
| Robert Wessman | Executive Chairman · Since at least Nov 2, 2026 |
Log in to ask 6ix AI your own questions about Alvotech.